850876-88-9

Usage

Uses

Used in Cancer Therapy:
RG7227, ITMN-191, and RO5190591 are used as targeted therapies for the treatment of various types of cancer. They work by inhibiting specific proteins and signaling pathways that are crucial for cancer cell growth and survival, leading to the suppression of tumor progression.
Used in Antiviral Therapy:
RG7227, ITMN-191, and RO5190591 are also used as antiviral agents for the treatment of viral infections, such as Hepatitis C. They target essential viral proteins and enzymes, inhibiting viral replication and reducing the viral load in infected individuals.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of RG7227, ITMN-191, and RO5190591, various drug delivery systems have been developed. These systems, including organic and metallic nanoparticles, aim to improve the delivery of these inhibitors to target tissues and cells, increasing their therapeutic potential.
Used in Pharmaceutical Research:
RG7227, ITMN-191, and RO5190591 are also used in pharmaceutical research as tools to study the molecular mechanisms underlying various diseases. Their ability to selectively target specific proteins and pathways makes them valuable for investigating the roles of these targets in disease pathogenesis and for identifying potential therapeutic targets for drug development.
Used in Diagnostic Applications:
These small molecule inhibitors can also be used in diagnostic applications, such as imaging techniques, to visualize the expression and activity of their target proteins in vivo. This can help in the early detection and monitoring of diseases, as well as in the assessment of treatment response.
Overall, RG7227, ITMN-191, and RO5190591 are versatile compounds with a wide range of potential applications in the fields of medicine, pharmaceutical research, and diagnostics. Their ability to target specific proteins and pathways involved in various diseases makes them promising candidates for the development of novel therapeutic agents and diagnostic tools.

Upstream product

• 154350-29-5 cyclopropanesulphonamide 
• 924307-72-2 C₃₂H₃₉FN₄O₇ 
• 924304-75-6 6-[[(tert-butoxy)carbonyl]amino]-2-[[(4-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-hexadecahydro-5,16-dioxo-(2R,6S,12Z,13aS,14aR,16aS)-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid 

Relevant academic research and scientific papers

Process for the preparation of a macrocycle

The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein R1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.

NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS

The invention relates to novel metathesis catalysts of the formula (I) a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis. The invention further relates to a process for the manufacture of a macrocyclic compound of formula (VII) which have the potential to be useful as HCV protease inhibitors.

Process for the preparation of a macrocycle

The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein R1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.

MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION

The present invention provides compounds of the general formulas I-IX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The present invention further provides treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.